First domestic quadrivalent HPV vaccine is approved for marketing.

According to the Chinese Biological Public Account, recently, the first domestic quadrivalent human papillomavirus vaccine independently developed by the Chengdu Biological Products Research Institute affiliated to the China National Pharmaceutical Group and the Chinese Academy of Biological Sciences has officially been approved for market by the National Medical Products Administration. This vaccine is prepared using a yeast expression system consistent with international standards. In addition to preventing high-risk HPV16 and HPV18 infections that lead to cervical cancer, this vaccine also provides protection against HPV6 and HPV11 infections that cause genital warts, filling the gap in protection against low-risk HPV infections related to genital warts provided by domestic bivalent vaccines.